The nation of Zimbabwe has rejected a major American healthcare agreement valued at $367m (£272m) over five years over Washington's demand for sensitive biological samples.
The decision was revealed following a official document dated December was leaked, which showed Head of State Emmerson Mnangagwa felt the agreement was "lopsided".
A government spokesman later explained that the US was seeking biological samples for scientific study and commercial gain while was not willing to share the resulting advantages from any future treatments.
"We are forced to start the challenging and unfortunate process of ending our health assistance in Zimbabwe," remarked US ambassador to Zimbabwe Pamela Tremont in a statement.
The US Embassy indicated the US had provided over $1.9bn for health programmes to Zimbabwe over the last two decades.
A medical body in Zimbabwe has called for further dialogue to reach a deal suitable to all parties so the nation's critical HIV programme can be sustained.
Broader Context
This development follows a comparable situation in neighbouring Kenya, where a high court halted a similar health funding agreement after legal challenges were raised about the safety of citizens' medical information.
Since returning to office recently, US President Donald Trump has drastically cut overseas assistance and shut down the key foreign aid agency.
USAID had managed aid for the US government, but Trump stated its spending was "wasteful" and his administration was seeking government-to-government deals to enhance transparency and responsibility.
Based on statements, 16 nations in Africa have so far agreed to these new health pacts, representing more than $18.3bn of fresh investment.
Specifics of the Declined Agreement
This assistance for Zimbabwe would have gone towards "tackling HIV/Aids, TB, malaria, maternal and child health, and preparing for epidemics".
"It is our view this cooperation would have delivered significant benefits for Zimbabwean communities, especially the 1.2 million currently receiving HIV treatment via American-funded initiatives," the Ambassador said.
However, official spokesman Nick Mangwana said the arrangement was "asymmetrical".
"Zimbabwe was being asked to share its genetic material and health information over an extended period, without any equivalent promise of benefiting from any scientific breakthroughs – like vaccines, diagnostics, or treatments – that could be developed from that provided information," Mangwana explained.
"Put simply, our nation would supply the raw materials for scientific discovery with no assurance that the end products would be available to our citizens if a new health crisis emerge."
Sovereignty and International Frameworks
He also said that the US's withdrawal from the World Health Organization (WHO) and its pursuit of one-on-one health agreements were upending frameworks previously established via the international health agency.
The spokesperson gave as an example its Pathogen Access and Benefit Sharing system created to deal with future pandemics.
"This framework is intended to ensure that when a nation provides its samples, the benefits – including medicines and cures – are distributed fairly, not monopolised solely by those with the capability to develop them."
The government's concerns over the US deal "are not meant as hostility towards the US," Mangwana stressed.
"We are open to continued discussions with our American counterparts on how subsequent co-operation might be designed in a way that respects the independence and interests of both nations."
Medical Community Response
A leading public health body expressed it acknowledged the government's concerns, but recommended that negotiations need to persist since a large portion of the country's Aids initiatives relied on international support.
"Where technical issues exist, such as those involving information security or agreement terms, these can frequently be resolved via detailed discussion and negotiated safeguards," it said.
The halted deal underscores the complex debate between receiving much-needed international aid and safeguarding local interests in an increasingly data-driven world.